BCAX Bicara Therapeutics Inc.
Price Chart
Executive Summary
Multiple C-suite executives at Bicara Therapeutics (BCAX) exercised stock options and sold shares in the open market over a 7-day period, generating over $483,000 in total proceeds from sales. The transactions were primarily driven by option exercises followed by corresponding sales to cover taxes and realize gains, with no open-market purchases observed.
Key Financial Metrics
Actionable Insight
Monitor for next earnings release or clinical trial updates — this activity appears to be routine option monetization rather than a signal of distress. However, absence of buying and concentration of selling among top executives warrants caution if repeated in future periods.
Key Facts
- CEO Mazumdar Claire and CFO Hyep Ivan exercised derivative securities (stock options) and sold the resulting shares in open-market transactions.
- Total open-market sales amounted to $483,168.03 across 30,200 shares sold at prices between $18.52 and $18.95.
- All transactions involving cash proceeds were sales; no open-market purchases were made.
- Non-cash transactions (codes M and A) totaled $81,611.52 in value, related to option exercises at $3.7898 strike price.
- Total insider selling represents approximately 0.048% of the company's $1.0B market cap — below the 0.1% threshold for materiality.
Financial Impact
$483,168 in open-market insider selling over 7 days, plus $81,612 in non-cash option exercises
Risk Factors
- Perception of lack of confidence if insiders continue to sell without reinvesting
- Potential for negative sentiment if no offsetting positive catalysts emerge soon
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (12 trades, 7d window) | cluster-BCAX-1774395923664 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $20.90 awaiting T+5 | awaiting T+5 | — | $21.69 (−3.80%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $21.58 $20.00 | ▼ −7.32% | ▼ −7.79% | $21.69 (+0.51%) |
|
May 11, 2026
4w ago
|
8-K
| $22.92 $19.29 | ▼ −15.84% | ▼ −15.75% | $21.69 (−5.37%) |
|
May 4, 2026
5w ago
|
Press Release
| $22.72 $22.92 | ▲ +0.88% | ▼ −2.06% | $21.69 (−4.53%) |
|
Apr 27, 2026
6w ago
|
DEFA14A
| $22.48 $22.72 | ▲ +1.09% | ▲ +0.69% | $21.69 (−3.49%) |
|
Apr 20, 2026
8w ago
|
Insider Cluster
| $21.28 $23.78 | ▲ +11.75% | ▲ +8.64% | $21.69 (+1.93%) |
|
Apr 15, 2026
8w ago
|
Insider Cluster
| $23.72 $23.63 | ▼ −0.38% | ▼ −2.02% | $21.69 (−8.56%) |
|
Apr 15, 2026
8w ago
|
Insider Cluster
| $23.72 $23.63 | ▲ +0.38% | ▲ +2.02% | $21.69 (+8.56%) |
|
Apr 3, 2026
10w ago
|
Press Release
| $20.85 $22.14 | ▲ +6.19% | ▲ +2.05% | $21.69 (+4.03%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $18.39 $19.04 | ▲ +3.53% | ▲ +7.10% | $21.69 (+17.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access